Biotie's clinical trial was a success [21.1.2010]
Turku-based drug discovery and development company Biotie Therapies reported on Tuesday November 19 that it has successfully completed a clinical trial with its fully human VAP-1 monoclonal antibody (BTT-1023) in rheumatoid arthritis patients.
– We are very pleased with the good tolerability and pharmacokinetic profile that we saw with BTT-1023 in this study, said Timo Veromaa, President and CEO of Biotie Therapies Corp.
Veromaa believed that the trial data, combined with signals of therapeutic activity, provide a good basis for proceeding into larger therapeutic trials with BTT-1023.
– We plan to analyze and discuss these data with our partner, Roche, to establish the optimal way to continue the clinical development program. We expect a decision from Roche, regarding its option right to in-license BTT-1023 at this stage of development, during the first half of 2010.
Biotie Therapies released its financial statement [2.3.2010]
Galilaeus Expands to Poland [18.2.2010]
Axel Technologies announced Fuugo with high hopes [15.2.2010]
Sudden landing at Science Park [2.2.2010]
Biotie's clinical trial was a success [21.1.2010]
First Christmas as a Doctor [5.1.2010]
Biotie raises 7,2 million euros [7.12.2009]
Tanja Dowe takes charge of Innomedica [20.11.2009]
Biotie Therapies Corp. interim report [23.10.2009]
IT Mill's Vaadin and Liferay Announce New Partnership [14.10.2009]
DelSiTech enters into research collaboration with Orion Corporation [7.10.2009]
Exploring a Cultural Experience [1.10.2009]
GenoSyst’s new project among the four best-rated Eurostars programs [15.9.2009]
QUATRX announces Ophena™ to be ready for filing New Drug Application [11.9.2009]
Chasing the accelerated evolution [1.9.2009]
Biotie Reaches Milestone in Wyeth Collaboration [31.8.2009]
Santhera Acquires Juvantia and Fipamezole [24.8.2009]
Ready to take-off [14.8.2009]
ArcDia Group ready for screening swine influenza [13.8.2009]